Cost-effectiveness of intravitreal ranibizumab with verteporfin photodynamic therapy compared with ranibizumab monotherapy for patients with polypoidal choroidal vasculopathy
JAMA Ophthalmology Jan 16, 2020
Doble B, Finkelstein EA, Tian Y, et al. - For patients with polypoidal choroidal vasculopathy (PCV), researchers sought to determine the incremental cost-effectiveness of intravitreal ranibizumab with verteporfin photodynamic therapy (combination therapy) vs ranibizumab monotherapy. For this investigation, all candidates were given 0.5 mg of intravitreal ranibizumab once every 4 weeks for the first 3 months. Standard fluence (50 J/cm3) photodynamic therapy with 6-mg/m2 verteporfin was administered once during the first 3 months and thereafter as needed for candidates receiving combination therapy. Findings revealed that combination therapy generated slightly higher quality-adjusted life-years (7.87 vs 7.85) at roughly equal lifetime costs during a lifetime horizon. Combination therapy may not be cost-effective for a 10-year horizon. The results suggested that PCV patients should consider combination therapy with ranibizumab as an alternative to standard care.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries